Search

Your search keyword '"Valadier, J"' showing total 13 results
Start Over Author "Valadier, J"
13 results on '"Valadier, J"'

11. Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals

Author

Henri Panjo, Guillemette Unal, François Simon, Jean-Christophe Plantier, Elodie Alessandri-Gradt, Diane Descamps, Charlotte Charpentier, Juliette Pavie, Marie Leoz, Francis Barin, Laurence Meyer, Clément Lefèvre, Orivao Study, Groupe de Recherche sur l'Adaptation Microbienne (GRAM 2.0), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Morphogénèse et antigénicité du VIH et du virus des Hépatites (MAVIVH - U1259 Inserm - CHRU Tours ), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Faculté de Médecine [Université Paris Diderot - Paris 7], Université Paris Diderot - Paris 7 (UPD7), Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), ORIVAO Study : Chennebault J, Fialaire P, Le Guillou-Guillemette H, Rehaiem S, Chanzy B, Clavere G, Gaillat J, Courdavault L, Genet P, Gerbe J, Benoit C, Honore Bouakline S, Waldner A, Bettinger D, Chirouze C, Bernard N, Reigadas S, Dupont X, Gaillard JL, Gault E, Reimann E, Otterbein G, Thomas L, Vaghefi P, Benoit M, Buthiot N, Goux A, Chambrin V, Deback C, Fior R, Raho Moussa M, Antoniotti O, Coban D, Cormerais L, Henquell C, Jacomet C, Lesens O, Chanoine N, Villmant A, Van Autreve JL, Bloch M, Ichou H, Manceron V, Mortier E, Zeng A, Bouvier-Alias M, Dominguez S, Lascaux-Cametez AS, Lelievre JD, Levy Y, Melica-Gregoire G, Pawlotsky JM, Pothier P, Waldner A, Inchiappa L, Verhaeghe A, Olivier B, Pathe JP, Berthe H, Mathez D, Favret V, Troisvallets D, Vandemeulebroucke E, Ceccaldi J, El Harif Z, Bocket L, Barbut P, Chaix F, Lambert C, Lambolez T, Miatezila J, Son O, Brunet P, Chappe C, Dhiver C, Lecomte V, Meddeb L, Poizot-Martin I, Tamalet C, Valadier J, Beck-Wirth G, Benomar M, Delarbre JM, Peter JM, Bevilacqua S, Venard V, Daneluzzi V, Idri N, Montoya B, Ferre V, Garnier E, Hue H, Larmet L, Point P, Raffi F, Reliqiet V, Rodallec A, Secher S, Amoyel P, Botton E, Janowski M, Le Cocguic Y, Deleplanque P, Descamps JM, Lapine M, Sunder S, Chansombat M, Charpentier C, Damond F, Diallo B, Duval X, Julia Z, Landman R, Legac S, Rioux C, Yeni P, Krivine A, Blanche P, Cros A, Gazalet P, Ghosn J, Krivine A, Sobel A, Bercot B, Diemer M, Parrinello M, Bey Boumezrag C, Bodard L, Gibert S, Huche FX, Raffenne L, Strebler M, Blanc C, Bourzam E, Hansel B, Lupin C, Wirden M, Bourzam E, Collias L, Effa J, Jung C, Pavie J, Pere H, Si Mohamed A, Delaugerre C, Gerard L, Loze B, Maylin S, Nabias R, Ponscarme D, Deleuze J, Rozenberg F, Bachour B, Bani-Sadr F, Chas J, Hamidi M, Kherallah L, Le Nagat S, Le Pendeven C, Moreau F, Nicolas JC, Schneider V, Tabone MD, Vaudre G, Giraudeau G, Le Moal G, Plainchamp D, Blondin G, Dorval I, Duthe JC, Perfezou P, Berger JL, Brodard V, Kmiec I, Rouger C, Strady C, Chappelin JM, Maillard A, Ratajczak M, Debab Y, De Oliveira F, Depatureaux A, Gueit I, Lemee V, Theron D, Pasdeloup I, Camps P, Bigaillon C, Ficko C, Imbert C, Rapp C, Grand C, Michau C, Bornarel D, Devillier P, Farfour E, Majerholc C, Vignon D, Zucman D, El Addouli M, Danjoux MF, Journe J, Leveneur Y, Marchou B, Nicot F, Prevoteau Du Clary F, Bonne S., Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Dupuis, Christine

Subjects
0301 basic medicine, Microbiology (medical), Cart, Adult, Male, medicine.medical_specialty, Anti-HIV Agents, Human immunodeficiency virus (HIV), HIV Infections, medicine.disease_cause, Gastroenterology, 03 medical and health sciences, Internal medicine, Medicine, Humans, Protease inhibitor (pharmacology), Survival analysis, Reverse-transcriptase inhibitor, business.industry, Genetic Variation, Middle Aged, Viral Load, 030112 virology, Antiretroviral therapy, 3. Good health, CD4 Lymphocyte Count, Regimen, 030104 developmental biology, Infectious Diseases, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, HIV-1, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, business, Viral load, medicine.drug
Abstract

International audience; Background:To obtain reliable clinical data of human immunodeficiency virus type 1 group O (HIV-1/O) infection, and immunovirological responses to combination antiretroviral therapy (cART), in a large series of 101 patients.Methods:Piecewise linear models were used to estimate CD4 count before and after cART initiation. Kaplan-Meier survival curves were used to estimate time to reach clinical stage C before antiretroviral therapy (ART) and to analyze time to achieve a plasma viral load (pVL)

Published
2018

12. [Thromboembolic disease and anomalies of fibrinolysis].

Author

Juhan-Vague I, Aillaud MF, Valadier J, Alessi MC, and Serradimigni A

Subjects
Glycoproteins blood, Humans, Plasminogen Activators antagonists & inhibitors, Plasminogen Inactivators, Thromboembolism etiology, Tissue Plasminogen Activator blood, Fibrinolysis, Thromboembolism blood
Abstract

Quantitative abnormalities of fibrinolytic system factors (tissue plasminogen activator (t-PA), plasminogen activator inhibitor (PA-inhibitor) are often found in the patients exhibiting an idiopathic thromboembolic pathology. Exploration of fibrinolytic system is performed by taking blood samples prior and after stimulation (after venous occlusion or DDAVP injection). Patients can be "good responders" (that is presenting with an increase of fibrinolytic activity after stimulation) or "bad responders". Among these latter (that is 30 p. 100 of cases), there are two groups: patients exhibiting an increase of PA inhibitor level, this concealing fibrinolytic role of t-PA released by stimulation (20 p. 100 of cases), patients failing to present any t-PA release through endothelial cells stimulation (10 p. 100 of cases). Furthermore, an hypofibrinolysis was demonstrated a long time ago, in certain thrombogenic conditions (post-operative period, obesity, elderly patients). Hypofibrinolysis was recently demonstrated, according to such conditions, as liable to an increase in the PA inhibitor levels. As pathogenic role of hypofibrinolysis is then demonstrated, therapeutic studies reducing the PA inhibitor level or increasing the t-PA rate produced and released by endothelial cells are to be developed.

Published
1986

13. Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1.

Author

Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, and Atlan C

Subjects
Adolescent, Adult, Female, Fibrinolysis, Humans, Male, Metformin pharmacology, Middle Aged, Glycoproteins blood, Insulin blood, Obesity blood, Plasminogen Activators antagonists & inhibitors, Plasminogen Inactivators, Triglycerides blood
Abstract

Low fibrinolytic activity, as measured by euglobulin (EFA), has been observed in obese subjects, and hypofibrinolysis may play a role in the pathogenesis of atherosclerosis and its complications. Blood fibrinolytic activity is regulated through a complex system of activators and inhibitors, especially plasminogen activator inhibitors (PA Inhibitors). In a group of 35 non-diabetic subjects with a wide range of body mass index (BMI), EFA was negatively correlated, and PA Inhibitor activity positively correlated, with BMI and plasma insulin levels. In a population of 49 non-diabetic obese women (differing from a control group of normal weight by lower EFA and higher level, of PA Inhibitor activity, plasma insulin and triglyceride), the PA Inhibitor activity was positively correlated with BMI, insulin and triglyceride. The increase in PA Inhibitor activity was associated with a high value of PA Inhibitor 1 antigen measured by an immuno-radiometric assay, indicating that the increased activity was due to a high level of circulating PA Inhibitor 1. Plasma insulin was lowered in obese non-diabetic subjects, without modification of the body weight, by a 24 hour fast or by treatment with Metformin. After 24 hours' fast, ten obese subjects had lower levels of insulin and PA Inhibitor activity and an increase in EFA. Treatment for 15 days by 1.75 g Metformin (or placebo), on a weight maintaining diet, induced, in the Metformin group, a decrease in plasma insulin, triglyceride and PA Inhibitor activity and an increase in EFA, while no change was observed in the placebo group.(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1987

Catalog

Books, media, physical & digital resources
See catalog results